| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/11/2000 | CA2640587A1 Gel compositions |
| 05/11/2000 | CA2639619A1 Gel compositions |
| 05/11/2000 | CA2349674A1 Capsules with porous mineral cortex |
| 05/11/2000 | CA2349505A1 Nucleic acid constructs for genetic immunization |
| 05/11/2000 | CA2349346A1 Lactone bearing absorbable polymers |
| 05/11/2000 | CA2349158A1 Compounds and methods for modulating claudin-mediated functions |
| 05/11/2000 | CA2348931A1 Dds compound and method for measurement thereof |
| 05/11/2000 | CA2348063A1 Method for preparing solid phase conjugate vaccines |
| 05/11/2000 | CA2347098A1 Compositions of and process for producing isotretinoin having low particle size |
| 05/11/2000 | CA2346897A1 Solid delivery systems for aroma ingredients |
| 05/11/2000 | CA2346857A1 Implant with cavities containing therapeutic agents |
| 05/11/2000 | CA2345697A1 Water-miscible pharmaceutical compositions of paclitaxel |
| 05/10/2000 | EP0998944A2 Enteric coated formulation of a benzimidazole derivative and method for preparation thereof |
| 05/10/2000 | EP0998943A1 A vitamine E acetate-based hydrophobic gel formulation for topical application |
| 05/10/2000 | EP0998942A1 Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method |
| 05/10/2000 | EP0998940A1 Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues |
| 05/10/2000 | EP0998933A1 Process for producing pharmaceutical compositions containing diphosphonates for oral administration |
| 05/10/2000 | EP0998932A1 Solid pharmaceutical dosage form containing diphosphonates or their salts and method for its production |
| 05/10/2000 | EP0998927A1 Absorption-enhancing composition for pantothenic acid derivative |
| 05/10/2000 | EP0998926A1 Oral preparation comprising S-(3-hydroxypropyl)-L-cysteine |
| 05/10/2000 | EP0998922A1 Aqueous coating composition and process for preparing solid pharmaceutical preparation |
| 05/10/2000 | EP0998917A1 Preparation of biodegradable microparticles containing a biologically active agent |
| 05/10/2000 | EP0998916A1 Medicinal compositions for application to mucosa |
| 05/10/2000 | EP0998915A1 Use of silicon gum to stabilize ascorbic acid, and new compositions containing these compounds |
| 05/10/2000 | EP0998914A1 Composition to enhance permeation of topical skin agents |
| 05/10/2000 | EP0998577A1 Conjugates of transporter peptides and nucleic acid analogs, and their use |
| 05/10/2000 | EP0998501A1 Cationic polymers, complexes associating said cationic polymers with therapeutically active substances comprising at least a negative charge, in particular nucleic acids, and their use in gene therapy |
| 05/10/2000 | EP0998487A2 Incorporation of pharmacologically active amino acid analogues into proteins |
| 05/10/2000 | EP0998306A1 Liposomal compositions for the delivery of nucleic acid catalysts |
| 05/10/2000 | EP0998305A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 05/10/2000 | EP0998304A1 Pharmaceutical compositions comprising cyclodextrins |
| 05/10/2000 | EP0998303A1 Biologically active materials |
| 05/10/2000 | EP0998297A2 Improved delivery of disease modifiers |
| 05/10/2000 | EP0998284A1 Composition comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 05/10/2000 | EP0998279A1 Pharmaceutical injection solution containing taxol |
| 05/10/2000 | EP0998272A1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| 05/10/2000 | EP0998271A1 Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| 05/10/2000 | EP0998267A1 Internally supported lipid vesicle systems |
| 05/10/2000 | EP0998266A1 Microcrystalline cellulose: alginate pharmaceutical suspensions |
| 05/10/2000 | EP0925065A4 Water miscible erythromycin solutions |
| 05/10/2000 | EP0685234B1 Drug composition containing nucleic acid copolymer |
| 05/10/2000 | CN1252840A Adenovirus vector specific for cells expressing alpha fetoprotein and methods of use thereof |
| 05/10/2000 | CN1252807A Neoglycoproteins |
| 05/10/2000 | CN1252721A Pharmaceutical composition |
| 05/10/2000 | CN1252720A Gastric-retained pharmaceutical compositions |
| 05/10/2000 | CN1252712A Use of micro particles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/10/2000 | CN1252709A Confectionary compositions |
| 05/10/2000 | CN1252708A Throat soothing compositions |
| 05/10/2000 | CN1252310A Intensified gelatinized preparation |
| 05/10/2000 | CN1252309A Stabilizer-containing live attenuated hepatitis A vaccine and its preparation |
| 05/10/2000 | CN1252277A Quick soluble breviscapine B tablet and its preparation |
| 05/10/2000 | CN1252272A Plaster for beauty, medicine or skin science |
| 05/09/2000 | US6060598 Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding |
| 05/09/2000 | US6060587 Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle |
| 05/09/2000 | US6060582 Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| 05/09/2000 | US6060518 Polymer compositions for chemotherapy and methods of treatment using the same |
| 05/09/2000 | US6060512 Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging |
| 05/09/2000 | US6060085 Dissolved drug that has the capacity to permeate the stratum corneum layer of the epidermis and become available systemically, and a drug in a microparticulate state that does not readily cross the stratum corneum |
| 05/09/2000 | US6060083 Topical DMSO treatment for palmar-plantar erythrodysethesia |
| 05/09/2000 | US6060077 Unit galenical formulation for local hormonotherapy of vaginal dryness |
| 05/09/2000 | US6060056 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule |
| 05/09/2000 | US6060053 Injectable chondrocyte-carrier suspension for treatment of vesicoureteral reflux and incontinence |
| 05/09/2000 | US6060050 Carrier acts as a growth or maintenance medium for microorganisms in the large bowel or other regions of the gastrointestinal tract. |
| 05/09/2000 | US6060048 Method for transplanting cells into the brain and therapeutic uses therefor |
| 05/09/2000 | US6060037 Conjugated compounds which comprise an st receptor binding moiety and a radiostable active moiety |
| 05/09/2000 | CA2151560C Insulin analog formulations |
| 05/09/2000 | CA2058940C Targeted liposomes and methods for liposome-protein coupling |
| 05/09/2000 | CA2011532C Formulation |
| 05/04/2000 | WO2000024896A2 Biological material for preparing pharmaceutical compositions for treating mammals |
| 05/04/2000 | WO2000024893A2 Methods and compositions for the prevention and treatment of anemia |
| 05/04/2000 | WO2000024784A1 Dextran-containing biologically active substance |
| 05/04/2000 | WO2000024751A1 Chelating agents for radioimmunotherapy |
| 05/04/2000 | WO2000024724A1 Thiazole-derivatives |
| 05/04/2000 | WO2000024452A1 Systems and compounds for drug delivery to interstitial regions of the myocardium |
| 05/04/2000 | WO2000024437A2 Textured and porous silicone rubber |
| 05/04/2000 | WO2000024426A1 Ribozymes used as prodrugs |
| 05/04/2000 | WO2000024425A1 Preservative system for topically administrable pharmaceutical compositions |
| 05/04/2000 | WO2000024424A1 Transmucosal sorbefacients comprising polyvalent unsaturated fatty acid and polymer gel and drugs containing the same |
| 05/04/2000 | WO2000024416A1 Remedies for bone metabolic errors |
| 05/04/2000 | WO2000024401A1 Fluticasone lotion having improved vasoconstrictor activity |
| 05/04/2000 | WO2000024386A1 Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs |
| 05/04/2000 | WO2000024385A1 Tablet for crunching with masked taste and instant release of active principle and method for making same |
| 05/04/2000 | WO2000024383A1 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 05/04/2000 | WO2000024379A1 Process for producing spherical fine particles containing drug |
| 05/04/2000 | WO2000024378A1 Compositions of microspheres for wound healing |
| 05/04/2000 | WO2000024377A1 Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates |
| 05/04/2000 | WO2000024376A1 Propofol composition |
| 05/04/2000 | WO2000024375A1 Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
| 05/04/2000 | WO2000024374A1 Controlled release liquid delivery compositions with low initial drug burst |
| 05/04/2000 | WO2000024373A1 O/w emulsion comprising an hydroxylated oil |
| 05/04/2000 | WO2000024366A1 Preparations for topical application of substances having antiandrogenic effect |
| 05/04/2000 | WO2000024362A2 Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use |
| 05/04/2000 | WO2000024360A2 Preparation and use of solidified oils |
| 05/04/2000 | WO2000024272A1 Sweetener |
| 05/04/2000 | WO2000024267A1 Gelatins with low allergenicity |
| 05/04/2000 | WO2000006579A3 Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity |
| 05/04/2000 | WO2000004862A3 Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| 05/04/2000 | WO2000003753A3 Microdisperse drug delivery systems |
| 05/04/2000 | WO2000002917A3 Compounds and methods for modulating cadherin-mediated functions |
| 05/04/2000 | WO1999066959A3 Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |